{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreih7vuu6diqqsiy4md7wuktgyyeeik7pxj7adajwtghh6g3xxye6wu",
    "uri": "at://did:plc:xyts6incftdyi5g2lym23hek/app.bsky.feed.post/3mfnsesoqq3b2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiaiecvlxspxkdcdxrtaqp3hdic5hysqanaxwfu32q2gefjrsgspkm"
    },
    "mimeType": "image/jpeg",
    "size": 145689
  },
  "path": "/videos/brewmarkets-what-novo-nordisks-glp1-price-cut-means-for-the-obesity-drug-market/",
  "publishedAt": "2026-02-24T22:27:39.000Z",
  "site": "https://nebula.tv",
  "tags": [
    "Money",
    "News"
  ],
  "textContent": "\n\nEpisode 130: Today, Ann digs into the Novo Nordisk vs Eli Lilly vs Pfizer news roundabout: with Novo’s share price dropping, now too are the list price of its popular obesity drugs - does that leave the entire sector vulnerable to… loss? Then we look at earnings from Constellation Energy, the largest operator of nuclear power plants in the U.S. - regulatory scrutiny builds as the sector grows in the AI age and residential customers see higher bills. Finally, we shine a light on Henry Schein and Factset and hit Parmount’s new salvo in the battle for Warner Brothers.",
  "title": "What Novo Nordisk's GLP-1 Price Cut Means for the Obesity Drug Market"
}